References
- Bendas G. Immunoliposomes. A promising aproach to targeting cancer therapy. BioDrugs 2001; 15: 215–224
- Chikh GG, Li WM, Schutze-Redelmaier M-P, Meunier J-C, Bally MB. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 2002; 1567: 204–212
- Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006; 8: 39–45
- Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003; 63: 3154–3161
- Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener RA. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer 2002; 87: 106–112
- Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Shalaby MR, Shao Y, Benz CC, Marks JD. Therapeutic efficacy of anti-erbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002; 1591: 109–118
- Nobs L, Buchegger F, Gurny R, Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 2004; 93: 1980–1992
- Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-HER2 immunoliposomes. J Control Release 2001; 74: 95–113
- Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004; 31(Suppl. 13)196–205
- Pastorino F, Brignole C, Marimpietri D, Sapra P, Hoase EH, Allen TM, Ponzoni M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003; 63: 86–92
- Rüger R, Müller D, Fahr A, Kontermann RE. Generation of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomes. J Drug Target 2005; 13: 399–406
- Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003; 42: 439–462
- Sapra P, Moase EH, Ma J, Allen TM. Improved thearapeutic responses in a xenograft model of human B lymphoma (Mamalwa) for liposomal vincristine versus liposomal doxorubicin targeted with anti-CD19 IgG2a ro Fab' fragments. Clin Cancer Res 2004; 10: 1100–1111
- Völkel T, Hölig P, Merdan T, Müller R, Kontermann RE. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 2004a; 1663: 158–166
- Völkel T, Müller R, Kontermann RE. Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library. Biochem Biophys Res Comm 2004b; 317: 515–521